Flagship Pioneering’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Flagship Pioneering’s Portfolio CDAK Stock Details CDAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,540,636	Closed	-$618K	–	11
2023 Q1	$618K	Hold	3,540,636	–	–	0.02%	11
2022 Q4	$1.38M	Hold	3,540,636	–	–	0.04%	12
2022 Q3	$2.76M	Buy	3,540,636 +933,333	+36%	+$1.96M	0.12%	12
2022 Q2	$7.51M	Hold	2,607,303	–	–	0.28%	11
2022 Q1	$16.3M	Hold	2,607,303	–	–	0.38%	11
2021 Q4	$29M	Hold	2,607,303	–	–	0.45%	10
2021 Q3	$42.6M	Hold	2,607,303	–	–	0.45%	11
2021 Q2	$48.3M	Hold	2,607,303	–	–	0.62%	11
2021 Q1	$39.3M	Hold	2,607,303	–	–	0.63%	11
2020 Q4	$84.2M	Buy	+2,607,303	New	+$34.5M	1.53%	9

Flagship Pioneering's CDAK Position: Q2 2023 in Review

Flagship Pioneering sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2023, closing a stake of 3,540,636 shares — an estimated $618K sold.

Flagship Pioneering first reported a position in CDAK in Q4 2020 and held it in 10 quarters. The position peaked at $84.2M in Q4 2020. 1 fund tracked by Wall St. Rank holds CDAK as of Q2 2023.

Flagship Pioneering reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Flagship Pioneering sold 3,540,636 Codiak BioSciences, Inc. Common Stock shares in Q2 2023, an estimated $618K.
Flagship Pioneering first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
Flagship Pioneering's Codiak BioSciences, Inc. Common Stock position peaked at $84.2M in Q4 2020.
1 fund tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2023.

Based on Flagship Pioneering's 13F filing for Q2 2023, filed 14 Aug 2023.